Year 2018 turned out to be superb for the pharma and biotech sector as far as FDA approvals were concerned. The regulatory agency gave nod to 59 novel drugs, well above 46 drugs approved in 2017. Immuno-oncology was once again the key focus area in 2018, be it in terms of scientific conferences, clinical trial collaborations, acquisitions or FDA approvals.
The recently announced $74 billion mega-merger of two cancer giants, Bristol-Myers (BMY – Free Report) and Celgene (CELG – Free Report) , and Glaxo (GSK – Free Report) and Lilly’s (LLY – Free Report) proposed acquisitions of smaller cancer biotech, TESARO and Loxo Oncology, respectively, clearly reflect the rising interest in this category.
While 2018 was a year focused on immuno-oncology, here we take a look at four therapeutic areas that we think will garner a lot of interest in 2019.